Home > News > pSivida Announces BrachySil(TM) Phase IIb Clinical Trials
October 31st, 2005
pSivida Announces BrachySil(TM) Phase IIb Clinical Trials
Abstract:
Global bio-nanotech company pSivida Limited today announced that Phase IIb clinical trials have commenced with BrachySil(TM) as a potential new brachytherapy treatment for inoperable primary liver cancer.
Source:
businesswire
Related News Press |
Nanomedicine
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Announcements
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |